Literature DB >> 8021605

Entire nucleotide sequence and characterization of a hepatitis C virus of genotype V/3a.

M Sakamoto1, Y Akahane, F Tsuda, T Tanaka, D G Woodfield, H Okamoto.   

Abstract

The entire nucleotide sequence of a hepatitis C virus (HCV) genome (NZL1) of genotype V/3a was determined from overlapping cDNA clones obtained from a human carrier in New Zealand. It comprised 9425 nucleotides (nt) including a 5'-untranslated region of 339 nt, a single large open reading frame encoding a polyprotein of 3021 amino acids, a 3'-untranslated region of 23 nt, and 3'-terminal poly(U) stretches of variable lengths. The NZL1 genome was compared with 15 HCV isolates of other genotypes for which the full-length sequence has been determined. It differed from them by 31.1 to 34.3% in nucleotide sequence identity and by 24.5 to 29.1% in amino acid sequence identity, confirming the distinction of genotype V/3a from the other isolates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8021605     DOI: 10.1099/0022-1317-75-7-1761

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

Review 1.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Full-genome nucleotide sequence of a hepatitis C virus variant (isolate name VAT96) representing a new subtype within the genotype 2 (arbitrarily 2k).

Authors:  E I Samokhvalov; M Hijikata; R I Gylka; D K Lvov; S Mishiro
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

3.  Genotyping hepatitis C virus isolates from Spain, Brazil, China, and Macau by a simplified PCR method.

Authors:  P V Holland; J M Barrera; M G Ercilla; C F Yoshida; Y Wang; G A de Olim; B Betlach; K Kuramoto; H Okamoto
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

4.  Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics.

Authors:  C Lin; B M Prágai; A Grakoui; J Xu; C M Rice
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Survey of type 6 group variants of hepatitis C virus in Southeast Asia by using a core-based genotyping assay.

Authors:  J Mellor; E A Walsh; L E Prescott; L M Jarvis; F Davidson; P L Yap; P Simmonds
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

6.  Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Authors:  Judith M Gottwein; Troels K H Scheel; Benoit Callendret; Yi-Ping Li; Heather B Eccleston; Ronald E Engle; Sugantha Govindarajan; William Satterfield; Robert H Purcell; Christopher M Walker; Jens Bukh
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

7.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.

Authors:  P Sarobe; C D Pendleton; T Akatsuka; D Lau; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

8.  The arginine-1493 residue in QRRGRTGR1493G motif IV of the hepatitis C virus NS3 helicase domain is essential for NS3 protein methylation by the protein arginine methyltransferase 1.

Authors:  J Rho; S Choi; Y R Seong; J Choi; D S Im
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups.

Authors:  H Tokita; H Okamoto; F Tsuda; P Song; S Nakata; T Chosa; H Iizuka; S Mishiro; Y Miyakawa; M Mayumi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

10.  Hepatitis C virus-encoded NS2-3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage.

Authors:  K E Reed; A Grakoui; C M Rice
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.